Dr. Jill N Carmody, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St, Suite 462, Newton, MA 02462 Phone: 617-964-1050 Fax: 617-964-6449 |
Jay H Kaufman, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2000 Washington St, Suite 462, Newton, MA 02462 Phone: 617-964-1050 Fax: 617-964-6449 |
Ralph H Hinckley, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2000 Washington St, White 548, Newton, MA 02462 Phone: 617-796-3937 Fax: 617-796-3938 |
Dr. Miriam Theresa Dougherty, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 2000 Washington St Ste 206, Newton, MA 02462 Phone: 617-332-6311 Fax: 617-243-5650 |
Marc A Leibole, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St, White 548, Newton, MA 02462 Phone: 617-796-3937 |
Nissim Joseph, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 73 Countryside Rd, Newton, MA 02459 Phone: 617-964-3795 |
Amita K Bhatt, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St, Suite 462, Newton, MA 02462 Phone: 617-964-1050 Fax: 617-964-6449 |
Jill A Smith, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St, Suite 462, Newton, MA 02462 Phone: 617-964-1050 Fax: 617-964-6449 |
News Archive
Professor Giampiero Favato is a health economist and director of doctoral programmes at Kingston University's Business School.
Just when some scientists were becoming more hopeful about finding a strategy to outwit HIV's ability to resist, evade and otherwise survive efforts to rid it from the body, another hurdle has emerged to foil their plans, new research from Johns Hopkins shows.
Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc., has announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market the LIFEPAK 15 monitor/defibrillator within the United States.
Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).
› Verified 5 days ago